Xenon Pharmaceuticals is a Canadian clinical-stage biopharmaceutical company that is developing treatments for neurological disorders. The company's clinical development pipeline includes XEN496 and XEN1101, both of which are Kv7 potassium channel openers in different stages of clinical trials. Xenon Pharmaceuticals also has product candidates like NBI-921352 and XEN007 that are in Phase II clinical trials.